Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Single-Arm, Phase 2 Study to Evaluate the Safety and Efficacy of IMMU-132 in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy

Clinical Trial Details

This clinical trial is for men age 18 and older with prostate cancer to check safety and tolerability of IMMU-132. 

Prostate cancer is the most common cancer in men in United States, after skin cancer, with more than 3 million cases per year. Initial therapies of prostate cancer include either surgical or chemical castration followed by androgen-deprivation therapy. Metastatic castration-resistant prostate cancer (mCRPC) is the resolution of the androgen receptor (AR) that leads cancer proliferation, tumor invasion and metastasis. There is no standard of care for mCRPC and efficacy of androgen receptor modulators and chemotherapy is moderate. Therefore, there is a need to find more effective treatments with fewer side effects. 

IMMU-132 is an antibody drug that stimulates the immune system and may stop cancer cells from growing. 

This study is a single-arm study. Patients will take the medication to intravenous injection (IV) for a 21-day cycle. All patients will be followed for survival until end of study or until sponsor ends the study. They will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects. 

Key Eligibility: 
  • Open to men 18 years and older 
  • Pathologically confirmed prostate cancer and demonstrated disease progression 
  • Documented metastatic disease 
  • Patients who have previously received enzalutamide, abiraterone, or apalutamide
  • Detailed eligibility reviewed when you contact the study team

Study contact by location

Upper East Side - Manhattan


Angela Tan, RN

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:





Open to Enrollment

Age Group